Tardive dyskinesia: a five year follow-up

Area of Science:

• Neuroscience
• Psychiatry
• Clinical Pharmacology

Background:

• Chronic schizophrenia treatment often involves long-term neuroleptic medication.
• Neuroleptic use is associated with potential adverse effects, including movement disorders.
• Tardive Dyskinesia (TD) is a significant concern in patients receiving antipsychotic therapy.

Purpose of the Study:

• To determine the prevalence of Tardive Dyskinesia (TD) in chronic schizophrenic patients undergoing prolonged neuroleptic treatment.
• To assess changes in TD severity over a five-year follow-up period.
• To evaluate the utility of different assessment scales in monitoring TD.

Main Methods:

• A cohort of chronic schizophrenic patients receiving neuroleptics was initially assessed in 1978.
• Patients with diagnosed TD were followed for five years, with reassessments at two and five years.
• The Smith scale was used for all assessments; the Abnormal Involuntary Movement Scale (AIMS) and videotaped interviews were added in the final assessment.

Main Results:

• The study assessed TD prevalence and progression in a specific patient group.
• Changes in TD severity were monitored over time using standardized scales.
• The high patient attrition rate impacted the study's ability to draw definitive conclusions.

Conclusions:

• While the study provides preliminary insights into TD progression in neuroleptic-treated schizophrenic patients, the findings are limited.
• The significant patient attrition rate prevents generalization of the results to the broader population.
• Further research with improved retention strategies is needed to understand TD trajectory.